Intensity Therapeutics Inc · Q2 2024 earnings

Briefing

Intensity Therapeutics' financial performance and corporate activities were reported for Q2 2024.

Intensity Therapeutics reported a net loss of $5.0 million for the second quarter of 2024, compared to a net loss of $3.7 million for the same period in 2023. As of June 30, 2024, cash, cash equivalents and marketable debt securities totaled $6.3 million, which is expected to fund operations into the first quarter of 2025. The company dosed its first patient in a Phase 3 study in metastatic soft tissue sarcoma and entered into a collaboration agreement with SAKK for a Phase 2 study in early-stage breast cancer.

• First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma.
• Collaboration agreement established with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized study in early-stage breast cancer in Europe.
• Cash and investments of $6.3 million are expected to fund operations into the first quarter of 2025.
• Net loss was $5.0 million for the three months ended June 30, 2024, compared to a net loss of $3.7 million for the three months ended June 30, 2023.

Headline financials

Revenue & EPS history

The Company expects that its cash, cash equivalents and marketable debt securities of $6.3 million as of June 30, 2024, will be sufficient to fund operations into the first quarter in 2025.